WHO R&D Portal

As rapid advances in biotechnology, genomics, synthetic biology, artificial intelligence and related life sciences continue to reshape global health and innovation, countries face a growing need to manage emerging risks without slowing scientific progress. Tools and knowledge developed for beneficial purposes can also pose risks if misused accidentally, inadvertently or deliberately. The World Health Organization (WHO) is responding by supporting Member States with practical and forward-looking approaches that strengthen safety, security and responsible oversight while enabling innovation. (September 2026)

More than 200 researchers and health care practitioners took part in a month-long programme connecting Kazakhstan’s clinical research community with expertise from WHO and international partners. The programme provided participants with opportunities to engage directly with international experts, exchange experience and explore current approaches and good practices in clinical research. (September 2026)

The World Health Organization (WHO) has prequalified the multi-dose vial presentation of the maternal respiratory syncytial virus (RSV) vaccine, RSVpreF (ABRYSVO®), marking a major step toward protecting more infants from severe respiratory illness and pneumonia globally. The new presentation is expected to make maternal RSV vaccination more affordable and easier to deliver, particularly in countries supported by Gavi, the Vaccine Alliance. (September 2026)